Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Medical General » Advances in Medicine and Biology. Volume 58 Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Brain, Body, Cognition - A continuation of Functional Neurology, Rehabilitation and Ergonomics
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
01.Supplementation with Arachidonic and Docosahexaenoic Acid for 7 Months Improves Visual Perception in 4-7 Year Old Children: A Prospective, Randomized, Double-Blind, Controlled Trial (pp. 113-134)
Notifications more
NotificationsNotify me of updates to Efficacy and Safety of the Express Implant in the Treatment of Primary and Secondary Glaucoma (pp. 187-196)
Tell A Friend
Tell someone you know about this product.
Efficacy and Safety of the Express Implant in the Treatment of Primary and Secondary Glaucoma (pp. 187-196) $100.00
Authors:  (Begoña Arana Larrea, Sergio Pinar-Sueiro, Ana Orive Bañuelos , Ignacio Castresana Jauregui, Alejandro Fonollosa, Marta Galdós Iztueta, Bárbara Berasategui Fernández, Lorea Martinez-Indart, Nerea Martinez Alday, Department of Ophthalmology, Cruces Hospital, Vizcaya, Spain, and others)
Background: To assess the long-term efficacy and safety of ExPRESS glaucoma shunts under a sclera flap for the treatment of primary and secondary glaucoma.
Methods: Retrospective study of 100 patients in whom the ExPRESS device was implanted (mean follow-up period of 31.44 months). This surgery was combined with phacoemulsification and intraocular lens implantation in patients with visually significant cataract. The intraocular pressure (IOP) was measured after one, three, six and twelve months, as well as in the last visit prior to the data collection. Statistical analysis was carried out using the Student‘s t and Wilcoxon tests.
Results: The mean IOPs were 26.53, 18.21, 17.78, 17.65, 17.18 and 15.94 at baseline, one, three, six and twelve months and during the last visit, respectively. The number of glaucoma medications decreased from 2.55 preoperatively to 0.34, 0.93, 1.29, 1.48 and 1.76 at the same points postoperatively. The IOP reduced the most in cases of glaucoma with higher baseline IOP (pseudoexfoliative and secondary to prior surgery). The mean percentage decrease in the IOP after one year was 35.7%. It was observed that, though the IOP remained stable, for longer follow up periods the number of glaucoma medications required to control it progressively increased. The most common postoperative complication was flattening of the anterior chamber, that could be managed fairly easily.
Conclusions: The ExPRESS shunt is an effective and safe technique for the treatment of glaucoma, the best candidates for surgery being the subset of patients with the highest baseline IOP. 

Available Options:
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

Efficacy and Safety of the Express Implant in the Treatment of Primary and Secondary Glaucoma (pp. 187-196)